Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOREAS phase 3 study of dupilumab in moderate-to-severe COPD with type 2 inflammation
MOH_2019-02-28_005962Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Dupixent 300 mg with Placebo (2 arms). Primary endpoints: Annualized rate of moderate or severe COPD exacerbations and Pre-bronchodilator FEV1 over 12 weeks. Started Feb 2019; status: active, not recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2019-02-28_005962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-28_005962.